AngioDynamics Announces Availability of the AquaLiner™ Hydrophilic Guidewire in the United States
AngioDynamics Announces Availability of the AquaLiner™ Hydrophilic Guidewire in the United States
Queensbury, NY; October 15, 2003 -- AngioDynamics, Inc., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) today announced the release for sale of the AquaLiner™ hydrophilic Ni-Ti alloy guidewire in the United States. The AquaLiner hydrophilic guidewire has a hydrophilic coating, which helps reduce friction when the guidewire comes into contact with fluids. This innovative feature allows a physician to move the guidewire through vessels and catheters with greater ease, simplifying guidewire placement in endovascular procedures. With today's announcement, customers can now purchase Aqualiner hydrophilic guidewires through the AngioDynamics direct sales force.
AngioDynamics previously announced its exclusive distribution agreement with Nipro Medical Corporation for the Aqualiner hydrophilic guidewire. Nipro Medical Corporation—a wholly owned subsidiary of Nipro Corporation of Osaka, Japan (Tokyo Premium Exchange: Nipro – 8086)—is a leading manufacturer and research developer of innovative medical technology.
Commenting for AngioDynamics, Michelle Mechaley, Director for Angiographic Products said, “The AquaLiner hydrophilic guidewire offers next generation performance through its superior design and coating endurance, providing the hydrophilic longevity that minimally invasive procedures demand. We are pleased to be bringing this important product to interventional radiologists in the United States. ”
For additional information on the AquaLiner hydrophilic Ni-Ti alloy guidewire, contact Michelle Mechaley at 1-800-772-6446, ext. 341, Email: mmechaley@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.
About E-Z-EM
E-Z-EM, Inc. (www.ezem.com) is a leading supplier of products used by radiologists, gastroenterologists and speech language pathologists for the diagnostic imaging of diseases and disorders of the GI tract, ranging from swallowing disorders (dysphagia) to colorectal cancers. E-Z-EM also is a third-party contract manufacturer of diagnostic contrast media, pharmaceuticals, non-prescription healthcare products, and defense decontaminants.
About Nipro Medical Corporation
Nipro Medical Corporation (www.nipro.com) is a fully owned subsidiary of Nipro Corporation (www.nipro.co.jp) of Osaka, Japan. Nipro Medical Corporation imports and distributes in the Americas the medical and disposable devices manufactured by its parent company in Japan. For additional information on Nipro Medical Corporation, please contact Philip Stocton, National Sales Manager, at 1-888-647-7698, ext. 239, Email: phils@nipromed.com or visit the Nipro web site at www.nipro.com.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) is a leading supplier of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and therapeutic treatment of peripheral vascular disease.
The statements made in this document contain certain forward‑looking statements that involve a number of risks and uncertainties. Words such as “expects”, “intends”, “anticipates”, “plans”, “believes”, “seeks”, “estimates,” or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended August 31, 2002, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.